Huons Biopharma Obtains Ecuador Approval for Botulinum Toxin 'Hutox'

Hutox.

[Asia Economy Reporter Lee Gwan-joo] Huons Biopharma announced on the 28th that its botulinum toxin product 'Hutox' (domestic name Riztox) has obtained product approval in Ecuador.

Since signing an exclusive supply contract with Ecuadorian aesthetic specialist company 'SALUDDERMA S.A.' in May 2020, Huons Biopharma has completed the final product approval and plans to enter the local market through Saludderma in the second half of this year.

With this product approval, Hutox has now been approved in a total of seven countries including Ecuador, Uzbekistan, Kazakhstan, Bolivia, Iraq, Azerbaijan, and the Dominican Republic.

Additionally, it recently obtained approval for a clinical trial plan (IND) for glabellar wrinkles from Taiwan's Center for Drug Evaluation (CDE) and plans to conduct a Phase 1 clinical trial.

Huons Biopharma plans to accelerate local approvals and clinical trials in European and Latin American countries, starting with ongoing clinical trials in China, while operating a second Hutox plant at EU GMP standards to actively expand into overseas markets.

A Huons Biopharma official stated, “We are strategically targeting emerging markets such as South America, which are highly evaluated for future growth potential, while also aiming at major botulinum toxin markets like the US and Europe. We plan to continuously develop overseas markets to strengthen our position in the botulinum toxin market.”

Hutox has three lineups of 50, 100, and 200 Units and has obtained indications for improving glabellar wrinkles and lateral canthal lines domestically.

This content was produced with the assistance of AI translation services.